Contribution of vaccine-induced immunity toward either the HA or the NA component of influenza viruses limits secondary bacterial complications.
Secondary bacterial infections contribute to morbidity and mortality from influenza. Vaccine effectiveness is typically assessed using prevention of influenza, not secondary infections, as an endpoint. We vaccinated mice with formalin-inactivated influenza virus vaccine preparations containing disparate HA and NA proteins and demonstrated an ability to induce the appropriate anti-HA and anti-NA immune profiles. Protection from both primary viral and secondary bacterial infection was demonstrated with vaccine-induced immunity directed toward either the HA or the NA. This finding suggests that immunity toward the NA component of the virion is desirable and should be considered in generation of influenza vaccines.
Huber
Victor C
VC
Division of Basic Biomedical Sciences, University of South Dakota, 414 E. Clark St., Vermillion, SD 57069, USA. victor.huber@usd.edu
Peltola
Ville
V
Iverson
Amy R
AR
McCullers
Jonathan A
JA
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D005260:Female; D006389:Hemagglutinins, Viral / Q000276:immunology*; D006801:Humans; D007252:Influenza Vaccines / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009439:Neuraminidase / Q000276:immunology*; D009976:Orthomyxoviridae Infections / Q000150:complications* / Q000276:immunology*; D018410:Pneumonia, Bacterial / Q000517:prevention & control*; D014764:Viral Proteins / Q000276:immunology*
D000914:Antibodies, Viral; D006389:Hemagglutinins, Viral; D007252:Influenza Vaccines; D014764:Viral Proteins; C458881:hemagglutinin fusogenic peptide, influenza virus; C487630:NA protein, influenza A virus; D009439:Neuraminidase